Victorian Breast and Oncology Care
Welcome,         Profile    Billing    Logout  
 5 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cescon, David
FINER, NCT04650581: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Active, not recruiting
3
250
Canada, RoW
Ipatasertib, Fulvestrant, Placebo
Canadian Cancer Trials Group, Hoffmann-La Roche
Breast Cancer
12/24
12/26
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
NCT04176848: CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

Active, not recruiting
2
15
Canada
CFI-400945, Durvalumab, IMFINZI
Canadian Cancer Trials Group, AstraZeneca, University Health Network, Toronto
Breast Cancer
09/22
12/24
Chipman, Mitchell
FINER, NCT04650581: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Active, not recruiting
3
250
Canada, RoW
Ipatasertib, Fulvestrant, Placebo
Canadian Cancer Trials Group, Hoffmann-La Roche
Breast Cancer
12/24
12/26
Balcewicz, Margaret
FINER, NCT04650581: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Active, not recruiting
3
250
Canada, RoW
Ipatasertib, Fulvestrant, Placebo
Canadian Cancer Trials Group, Hoffmann-La Roche
Breast Cancer
12/24
12/26

Download Options